Related references
Note: Only part of the references are listed.Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline BRCA Pathogenic Variant
Jennifer K. Litton et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer A Secondary Analysis of the GeparOcto Randomized Clinical Trial
Esther Pohl-Rescigno et al.
JAMA ONCOLOGY (2020)
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
M. E. Robson et al.
ANNALS OF ONCOLOGY (2019)
Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy
Charlie Gourley et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?
Benedetta Pellegrino et al.
ESMO OPEN (2019)
BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
Peter A. Fasching et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study
Ellen R. Copson et al.
LANCET ONCOLOGY (2018)
Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
Carsten Denkert et al.
LANCET ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Andrew Tutt et al.
NATURE MEDICINE (2018)
Quality of life with talazoparib versus physician's choice of chemotherapy in patients wits advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA ease III trial
J. Ettl et al.
ANNALS OF ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S. Loibl et al.
ANNALS OF ONCOLOGY (2018)
Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
Paul Gass et al.
BMC CANCER (2018)
Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial
Yung-Jue Bang et al.
LANCET ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer Secondary Analysis of the GeparSixto Randomized Clinical Trial
Eric Hahnen et al.
JAMA ONCOLOGY (2017)
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
Melinda L. Telli et al.
CLINICAL CANCER RESEARCH (2016)
Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
Carsten Denkert et al.
MODERN PATHOLOGY (2016)
Outcome after neoadjuvant chemotherapy in young breast cancer patients: a pooled analysis of individual patient data from eight prospectively randomized controlled trials
Sibylle Loibl et al.
BREAST CANCER RESEARCH AND TREATMENT (2015)
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza et al.
LANCET ONCOLOGY (2015)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
Gunter von Minckwitz et al.
LANCET ONCOLOGY (2014)
Predictive Factors for Response to Neoadjuvant Therapy in Breast Cancer
Sibylle Loibl et al.
ONCOLOGY RESEARCH AND TREATMENT (2014)